WASHINGTON (April 14, 2025) — The Association for Accessible Medicines today commented on an announcement by the Department of Commerce beginning a Section 232 investigation into possible tariffs and other trade remedies with the goal of encouraging more domestic manufacturing of pharmaceuticals.
“AAM and the generics and biosimilars industry look forward to working with the Commerce Department and the White House to engage constructively on ways to incent more domestic investment in the medicines supply chain,” said John Murphy III, President and CEO of the Association for Accessible Medicines. “As we have said countless times: a resilient and reliable generic medicines supply chain is critical to patient health, U.S. healthcare and national security interests. Tariffs, however, will only amplify the problems that already exist in the U.S. market for affordable medicines.
“Without substantive regulatory and reimbursement changes to the U.S. market, tariffs will exacerbate current shortages that hinder patient access today. Instead, we urge the Administration to work with us on a suite of reforms that prioritize patients, national security, and ultimately will lead to more resilient and reliable access here in the U.S. As was the case in the previous Trump Administration, we also support exemptions and carve-outs from tariffs for essential and short-supply medicines as well as for the base ingredients in those medicines.”
AAM Release on February Tariffs
The Association for Accessible Medicines, your generics and biosimilars industry, is driven by the belief that access to safe, quality, effective medicine has a tremendous impact on a person’s life and the world around them. AAM represents the manufacturers of finished generic pharmaceuticals and biosimilars, manufacturers of bulk pharmaceutical chemicals, and suppliers of other goods and services to the generic industry. Generic pharmaceuticals are 90 percent of prescriptions dispensed in the U.S. but only 13.1 percent of total drug spending.
For media inquiries, contact media@accessiblemeds.org.
About the Biosimilars Council
The Biosimilars Council, a division of the Association for Accessible Medicines, works to ensure a positive environment for patient access to biosimilar medicines. The Biosimilars Council is the leading source for information about the safety and efficacy of more affordable alternatives to costly brand biologic medicines. Areas of focus include public and health expert education, government affairs, legal affairs, and regulatory policy. More information is available at biosimilarscouncil.org.
